Verdient Science LLC
SPEAKER
MEDICINE
The pharmacology of delta-8-tetrahydrocannabinol (Δ8-THC): a review of 80 years of studies
The objective of this analysis was to comprehensively review the scientific literature on the pharmacology of delta-8-THC (Δ8-THC) and how it compared to Δ9-THC. PubMed was searched for all publications related to in vitro binding and functional assays, in vivo assays, and clinical studies of Δ8-THC.
Learning Objectives:
1. Understand how the pharmacokinetics and pharmacodynamics (PK/PD) of delta-8-THC are similar and different to the PK/PD of delta-9-THC
2. Identify what we still do not know about the pharmacology of delta-8-THC and how we can fill these gaps with new studies
BIO
Dr. Tagen is a partner at Verdient Science LLC, a consulting firm focused on the pharmacology of cannabinoids and psychedelics. He has spent 14 years working in clinical and translational research in a variety of therapeutic areas, including pain, inflammation, and cancer. Dr. Tagen earned a B.A. in Neuroscience and a Ph.D. in Pharmacology & Experimental Therapeutics.
View CannMed Resources Below:
ATTENDANCE IS LIMITED. THE OPPORTUNITIES ARE NOT.
